Intratumoral Delivery of MDNA55, an Interleukin-4 Receptor Targeted Immunotherapy, by MRI-Guided Convective Delivery for the Treatment of Recurrent Glioblastoma
• MDNA55 is co-infused with Gadolinium-based contrast agent (GdDTPA) to allow real-time monitoring of drug distribution and to optimize intratumoral catheter placement. Evaluation of drug distribution patterns and safety data suggested that improvements to drug distribution could be further enhanced by moving to a fixed volume of 60 mL administered via 4 catheters and allowing placement outside the peritumoral area. (Table 1 , Group 2). • No clinically significant laboratory abnormalities.
SAFETY OF MDNA55
• Drug-related adverse events were primarily neurological/aggravation of preexisting neurological deficits characteristic with GBM. • Realtime imaging with co-infused GdDTPA distribution enables optimization of catheter placement and infusion parameters. Catheter trajectory planning and infusate distribution was performed using Brainlab iPlan® Flow software. Percent coverage was calculated based on the fraction of the target volumes covered by the determined gadolinium distribution at end of infusion (example shown below).
Tumor Volume -4.7 cm 3 Tumor Diameter -2.3 cm 3 Vi -60 cm 3 Vd of Gad -95 cm 3 Vd/Vi ratio -1.6 Tumor Coverage -95%
*Concentration of gadolinium was reduced to 2 mmol in later versions of the protocol due to FDA and EMA recommendation to minimize exposure in humans.
Although increased infusion volumes (exceeding 40 mL) led to increased mean volume of distribution, it did not improve the target percentage coverage of the enhancing lesion (Table 3 , Fig 2) .
Needs discussion
EFFICACY OF MDNA55: PATTERNS OF RESPONSE
Case 1: Subject experienced increase in contrast enhancement lasting over 120 days, due to pseudo-progresssion, the result of local tissue reaction to inflammatory infiltration seen with immunotherapies. Over the following 8 months, subject experienced continual tumor decline eventually reaching to below baseline. The SAE of Hydrocephalus was assessed to be unrelated to study drug and the infusion procedure by the sponsor due to temporal gap. 
RESULTS:

